🔗 Share this article World Health Organization Issues Alert Over Acute Lack of Obesity Injections Less than a tenth of individuals who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it publishes its inaugural recommendations on the therapies. Given over a billion people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs. According to projections, over two billion will be living with obesity by 2030 unless action is taken. "The new guidelines affirms that excess weight is a long-term condition that can be treated with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can help people shift significant weight, says the body. GLP-1 Therapy Shortage Even in the present most favorable scenario, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of the global need, as stated by the WHO. The guideline encourages governments and firms to widen availability, through measures such as patent sharing. The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. How Weight-Loss Jabs Operate These medications replicate a natural hormone to slow digestion, curb appetite and enhance satiety so users eat less. People usually see weight reduction after several weeks of beginning the regular doses. Studies points to users may regain a significant portion within a year of halting the drug, when their normal food cravings resume. To be carrying excess weight raises your chance for developing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts people in all nations and was responsible for millions of deaths worldwide in 2024, as per the health agency.
Less than a tenth of individuals who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it publishes its inaugural recommendations on the therapies. Given over a billion people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs. According to projections, over two billion will be living with obesity by 2030 unless action is taken. "The new guidelines affirms that excess weight is a long-term condition that can be treated with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can help people shift significant weight, says the body. GLP-1 Therapy Shortage Even in the present most favorable scenario, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of the global need, as stated by the WHO. The guideline encourages governments and firms to widen availability, through measures such as patent sharing. The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. How Weight-Loss Jabs Operate These medications replicate a natural hormone to slow digestion, curb appetite and enhance satiety so users eat less. People usually see weight reduction after several weeks of beginning the regular doses. Studies points to users may regain a significant portion within a year of halting the drug, when their normal food cravings resume. To be carrying excess weight raises your chance for developing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some cancers. Excess weight impacts people in all nations and was responsible for millions of deaths worldwide in 2024, as per the health agency.